title: Conflicting signals on US accelerated approvals.
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Fox
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D017277:Drug Approval; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000592:standards; D015507:Drugs, Investigational / Q000494:pharmacology; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D011799:Quinazolines / Q000494:pharmacology; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D016861:Cyclooxygenase Inhibitors; D015507:Drugs, Investigational; D011799:Quinazolines; D000077156:Gefitinib